Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05413044 · ClinicalTrials.gov registry record
A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 140,706
- Enrollment target
NCT05413044 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 140,706 participants.
The verdict
NCT05413044 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 140,706 participants
- Enrollment target
Study Summary
The purpose of this study is to collect real-world data in order to estimate the frequency of overall malignancies, melanoma, basal cell carcinoma, and squamous cell carcinoma in participants with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) enrolled in the SRQ Register in Sweden.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140,706 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2025-10-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05413044
The ClinicalTrials.gov registry entry for NCT05413044 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 140,706 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05413044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05413044 about?
NCT05413044 is a clinical study titled "A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register". The purpose of this study is to collect real-world data in order to estimate the frequency of overall malignancies, melanoma, basal cell carcinoma, and squamous cell carcinoma in participants with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) enrolled in the SRQ Register in Sweden.
What is the current status of trial NCT05413044?
This trial is currently completed. The enrollment target is 140,706 participants. The study started on 2019-07-01. Estimated completion is 2025-10-31.
Who is sponsoring clinical trial NCT05413044?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.